New Drugs in Development to Stop Muscle Loss During GLP-1 Weight Loss
NorthStrive Biosciences patents two muscle-preserving compounds targeting sarcopenia and GLP-1-related muscle loss in humans.
Summary
A biotech company called NorthStrive Biosciences has filed two U.S. patent applications for experimental drugs designed to protect muscle mass during weight loss. The compounds, EL-22 and EL-32, are aimed at people using GLP-1 drugs like Ozempic or Wegovy, who often lose significant muscle alongside fat. EL-22 works by targeting myostatin, a protein that limits muscle growth, while EL-32 uses engineered bacteria to block both myostatin and activin A, two key muscle-loss signals. The filings also explore combining these compounds with apelin or ursolic acid for added effect. The company is expanding from animal health into human pharmaceuticals, with potential applications beyond obesity including sarcopenia, malnutrition, and muscle wasting from inactivity.
Detailed Summary
As GLP-1 drugs like semaglutide become mainstream weight-loss tools, a growing concern is emerging: these medications can cause significant loss of lean muscle mass alongside fat. For people already at risk of sarcopenia or age-related muscle decline, this side effect could undermine the long-term health benefits of weight loss. NorthStrive Biosciences is now moving to address this gap with two novel drug candidates.
The company filed U.S. patent applications on June 18, 2026, for EL-22 and EL-32, two distinct approaches to preserving muscle during weight loss therapies. EL-22 centers on myostatin-derived peptide constructs, including multimers and fusion proteins, designed to inhibit myostatin, a signaling protein that naturally suppresses muscle growth. Blocking myostatin has long been studied as a strategy to build or preserve muscle.
EL-32 takes a more biological approach, using microorganisms engineered with surface display technology to target both myostatin and activin A, another muscle-wasting signal. Notably, the platform uses lactic acid bacteria such as Lactobacillus paracasei, which may allow for oral delivery, making administration more accessible than injectable alternatives. Both compounds also explore co-administration with apelin, a peptide linked to muscle function, and ursolic acid, a plant compound with known anabolic properties.
The patents cover multiple delivery formats including oral, injectable, nasal, and topical routes, suggesting flexibility for clinical application. Importantly, the filings expand NorthStrive's existing animal health intellectual property into the human pharmaceutical space, covering conditions such as sarcopenia, obesity-related muscle loss, neurogenic atrophy, and malnutrition.
However, these are patent filings, not clinical trial results. No human efficacy or safety data has been published. The science underpinning myostatin inhibition has shown mixed results in past trials. Investors and health-conscious readers should treat this as early-stage pipeline news rather than a near-term therapeutic breakthrough.
Key Findings
- EL-22 targets myostatin via peptide constructs to preserve muscle during GLP-1-driven weight loss
- EL-32 uses engineered Lactobacillus bacteria to block both myostatin and activin A muscle-wasting signals
- Oral delivery formats are included, potentially improving accessibility over injectable muscle-preserving drugs
- Co-administration with apelin and ursolic acid is claimed, offering potential synergistic muscle protection
- Target conditions include sarcopenia, obesity-related muscle loss, malnutrition, and neurogenic atrophy
Methodology
This is a news report from Longevity.Technology summarizing a corporate patent filing announcement. The evidence basis is the patent applications themselves, not peer-reviewed clinical data. No independent scientific validation or human trial results are referenced.
Study Limitations
These are patent filings only; no human clinical trial data exists for EL-22 or EL-32. Myostatin inhibition has historically shown limited efficacy in human trials despite promising preclinical results. Readers should await peer-reviewed study publications before drawing conclusions about therapeutic potential.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.